[EATG Global HIV News daily digest] Digest #35-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -





Latest Headlines




  Single-dose HIV DNA vaccine induces long-lasting immune response in monkeys
  Prevention Thursday 25 February 2010
					
  
For the first time researchers from the U.S. and abroad have shown a
single-dose HIV DNA vaccine can induce a long-lasting HIV-specific
immune response in nonhuman primates, a discovery that could prove
significant in the development of HIV vaccines.
  SOURCE:
ScienceDaily




  Coburn: Skip Europe AIDS meeting
  World Policy Thursday 25 February 2010
					
  
An upcoming international AIDS conference in Europe should be canceled,
says a Republican senator who wants organizers to use money for travel
and meetings on treatment and research instead. 
  SOURCE:
Washington Times




  Uzbekistan jails AIDS advocate over work: activists 
  World Policy Thursday 25 February 2010
					
  
An AIDS activist in Uzbekistan has been sentenced to seven years in
prison for writing a brochure that authorities said would promote
antisocial behaviour, activists said Thursday.
  SOURCE:
France24




  Regulus could get $150M from expanded partnership with GlaxoSmithKline for hepatitis C work
  Hepatitis Thursday 25 February 2010
					
  
Regulus is a joint venture between Alnylam Pharmaceuticals and Isis
Pharmaceuticals. It develops drugs that use microRNA technology, which
can turn parts of genes on or off to treat diseases.
  SOURCE:
Los Angeles Times




  Tough IP health provisions in Europe’s Colombia/Peru trade deal 
  EU Policy Thursday 25 February 2010
					
  
Far-reaching provisions on the patenting of medicine have been inserted
into a controversial free trade agreement between the European Union
and Colombia and Peru.
  SOURCE:
Intellectual Property Watch




  ANA598 demostrates 73% cEVR in combination with interferon and ribavirin
  Hepatitis Thursday 25 February 2010
					
  
No viral rebound observed during 12 weeks of ANA598 dosing; Positive safety data with AE profile comparable to control group.
  SOURCE:
Anadys Pharmaceuticals, Inc.




  α-defensins1-3 may be potential prophylactic agents in treatment of HIV/AIDS
  Basic Science Thursday 25 February 2010
					
  
For the first time the increased α-defensins1-3 production by dendritic cells shows a slower progression of the infection.
  SOURCE:
The Medical News




  Bone fracture risk higher among people living with HIV
  Treatment Thursday 25 February 2010
					
  
People living with HIV face a higher risk of bone fractures than people of similar ages in the general population.
  SOURCE:
AIDSmeds.com




  Treatments for HIV/TB co-infection should start at the same time: study
  Tuberculosis & Malaria Thursday 25 February 2010
					
  
In patients with HIV and tuberculosis (TB) whose CD4 cell counts are
below 500/mm3, mortality is increased if antiretroviral therapy is
delayed until TB treatment is finished, according to research from
South Africa.
  SOURCE:
Medscape Today


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100225/4ab63a6e/attachment-0001.html>